1298086-15-3

Usage

Uses

Used in Organic Chemistry Research:
2-((benzyloxy)(4-ethoxyphenyl)methyl)-4-bromo-1-chlorobenzene is used as a research compound for exploring its chemical properties and reactivity due to its complex molecular structure and the presence of multiple functional groups.
Used in Materials Science:
In the field of materials science, 2-((benzyloxy)(4-ethoxyphenyl)methyl)-4-bromo-1-chlorobenzene is used as a precursor or building block for the development of new materials with specific properties, such as those with unique electronic, optical, or mechanical characteristics.
Used in Pharmaceutical Industry:
2-((benzyloxy)(4-ethoxyphenyl)methyl)-4-bromo-1-chlorobenzene is used as an intermediate in the synthesis of pharmaceutical compounds, potentially contributing to the development of new drugs with novel therapeutic properties.
Used in Chemical Synthesis:
2-((benzyloxy)(4-ethoxyphenyl)methyl)-4-bromo-1-chlorobenzene is used as a reactant or catalyst in various chemical synthesis processes, where its unique structure and functional groups can facilitate specific reactions or improve the efficiency of the synthesis.
Used in Analytical Chemistry:
2-((benzyloxy)(4-ethoxyphenyl)methyl)-4-bromo-1-chlorobenzene can be employed as a reference compound or standard in analytical chemistry for the calibration of instruments or the development of new analytical methods.

Upstream product

• 1280647-32-6 (5-bromo-2-chlorophenyl)(4-ethyloxyphenyl)methanol 
• 100-39-0 benzyl bromide 
• 461432-22-4 (5-bromo-2-chlorophenyl)(4-ethyloxyphenyl)methanone 
• 41842-30-2 4-ethoxyphenylmagnesium bromide 
• 189628-37-3 2-chloro-5-bromobenzaldehyde 
• 100-51-6 benzyl alcohol 

Downstream Products

• 461432-25-7 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 461432-26-8 dapagliflozin 
• 1079083-63-8 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-hydroxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 915095-99-7 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-trityl triacetate 
• 1417573-74-0 1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucopyranoside 

Relevant academic research and scientific papers

Preparation methods of SGLT-2 diabetes inhibitors and intermediates thereof

The invention provides a preparation method of an intermediate compound 7 of an SGLT-2 diabetes inhibitor dapagliflozin and an intermediate compound 8 of a SGLT-2 diabetes inhibitor empagliflozin, and new synthesis method of two final products. The preparation method comprises the following steps: carrying out carbonyl group reduction and hydroxyl group protection on a (5-halo-2-chlorophenyl)(4-ethoxyphenyl)ketone compound 1 used as an initial raw material to obtain a Grignard addition reaction key compound 4, and carrying out Grignard addition and acetylation to obtain the compound 7 and the compound 8. The dapagliflozin and the empagliflozin are respectively prepared from the compound 8. The methods have the advantages of simplicity in operation, high yield, high purity of the obtained products, and suitableness for amplified production.

Commercial route research and development for SGLT2 inhibitor candidate ertugliflozin

A practical synthesis of SGLT2 inhibitor candidate ertugliflozin (1) has been developed for potential commercial application. The highly telescoped process involves only three intermediate isolations over a 12-step sequence. The dioxabicyclo[ 3.2.1]octane motif is prepared from commercially available 2,3,4,6-tetra-O-benzyl-D-glucose, with nucleophilic hydroxymethylation of a 5-ketogluconamide intermediate as a key step. The aglycone moiety is introduced via aryl anion addition to a methylpiperazine amide. High chemical purity of the API is assured through isolation of the crystalline penultimate intermediate, tetraacetate 39. A cocrystalline complex of the amorphous solid 1 with L-pyroglutamic acid has been prepared in order to improve the physical properties for manufacture and to ensure robust API quality.

DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES

Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).